The diagnosis value of dopaminergic responsiveness of Parkinson’s disease： a systematic review and meta-analysis
Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Effect of levodopa on the interpretation of social interactions in people living with Parkinson’s disease
Objective: Better understand the social interactions by assessing the effect of oral levodopa on the social cognition abilities in fluctuating PD patients without significant cognitive disorder.…Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study
Objective: Primary objectives were to assess the feasibility and safety of LCIG home titration with use of telemedicine-assisted (TM) technology, and patient/caregivers satisfaction. Secondly, to…Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult
Objective: To evaluate effects of acute levodopa administration on frequency content of intracranial local field potentials in a dystonic young adult. Background: Levodopa is the…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial
Objective: Evaluate the frequency of adverse events over time with foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (PD) in a phase 3, open-label safety…Functional movement disorders in dopa-responsive dystonia – A case series with implications for diagnosis and treatment
Objective: A detailed clinical characterization of functional movement disorders (FMD) in dopa-responsive dystonia (DRD) patients. Background: FMD are one of the most common conditions in…Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa
Objective: To compare the effect of intravenous (DIZ101) and subcutaneous (DIZ102) continuous 16h infusion of a continuously buffered acidic levodopa/carbidopa solution with levodopa/carbidopa intestinal gel…Sex differences in motor response to levodopa in early Parkinson’s disease
Objective: To evaluate differences between males and females in trajectory of motor response to levodopa in early Parkinson’s disease (PD). Background: Previous research has shown…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 57
- Next Page »